Etiology of Lymphopenia in Covid19 Infection

Lymphopenia Clinical Trial

Official title:

Study of the Etiology of Lymphopenia in Covid19 Viral Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04404608
• Other study ID #: 201920008.2
• Status: Completed
• Start date: June 1, 2020
• Est. completion date: December 1, 2021

Study information

• Verified date: July 2022
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study of the cause of lymphopenia in Covid19 viral infection will be done in 3 cohorts. First cohort will be patients asymptomatic or with mild symptoms. Second cohort will be patients with severe illness and admitted to ICU. Third cohort will be patients critically ill and on artificial ventilation.

Description:

Each cohort will include 30 patients. Complete blood count in all patients will be done daily in all patients. Bone marrow aspiration cytology will be done in some selected patients especially those with lymphopenia less than 1000 per cubic mm. Correlation of the degree of lymphopenia with the status of the patients will be done. Also correlation will be done about the relation of recovery of lymphopenia and status of the patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 172
• Est. completion date: December 1, 2021
• Est. primary completion date: June 1, 2021
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Any patient admitted with the diagnosis of Covid19 viral infection

Exclusion Criteria:

• Any patient who died within one day of admission

Related Conditions & MeSH terms

• Lymphopenia

Intervention

Diagnostic Test:
• Complete blood picture, bone marrow aspiration cytology
none except the regular routine investigations in such cases

Locations

Country	Name	City	State
Egypt	National Cancer Institute Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Dr Medhat Khafagy

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death or recovery	Follow up	Up to 24 weeks